What DCx Biotherapeutics does

DCx Biotherapeutics Corporation is a preclinical-stage biotechnology company founded in May 2025 and headquartered in Vancouver, British Columbia, with an R&D facility in Montreal acquired from Repare Therapeutics. The company develops Multi-Modal Antibody Drug Conjugates (MM-ADCs) — next-generation precision drug conjugates that simultaneously target genetically-defined intracellular and cell-surface proteins to treat cancers driven by specific genetic lesions. Its target patient population is oncology patients harboring actionable mutations with high unmet need.

DCx's discovery engine is the proprietary MuSiC™ Platform, which integrates CRISPR-based high-throughput functional screening with bioinformatics and machine learning to identify lesion-specific targets that are not addressable by traditional ADC approaches. The MuSiC™ platform incorporates non-exclusively licensed SNIPRx® and STEP2 discovery platforms acquired from Repare Therapeutics. Its therapeutic design pairs functional antibodies with the proprietary CLARINET™ (Cancer Lesion Adaptive Release via Intracellular Enzyme Trigger) payload technology — a dual-logic gate that uses lesion-upregulated intracellular metabolic enzymes to selectively activate masked cytotoxics, materially expanding the therapeutic window relative to conventional ADCs.

DCx is a privately held, venture-backed company with no commercial products and no revenue. The company was launched out of Amplitude Ventures (co-founding investor, >$500M AUM) as the sixth company built via Amplitude's innovation platform, led by CEO Ali Tehrani and a co-founding team drawn from Zymeworks and Abdera. Future monetization is expected to come from out-licensing of development candidates, clinical and commercial milestone payments, and royalties from pharma partners; currently all activity is R&D-focused, with multiple development candidates targeted over a three-year horizon. The customer base today consists of scientific and capital partners (Repare Therapeutics, Amplitude Ventures) rather than paying end customers.

Name

DCx Biotherapeutics

Legal name

DCx Biotherapeutics Corporation

Website

https://dcxbio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

DCx Biotherapeutics is a preclinical-stage Canadian biotechnology company developing multi-modal antibody drug conjugates that combine functional antibodies with proprietary CLARINET™ payloads to target genetically-defined cancers, using its CRISPR/ML-enabled MuSiC™ discovery platform.

Ownership category

akta.pro rank

Product category

Oncology Biotherapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Antibody drug conjugates
• Oncology therapeutics
• Precision medicine
• Biopharmaceutical research
• Multi-modal ADCs

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. No current revenue: DCx Biotherapeutics is a preclinical-stage discovery and translational company. No commercial products or revenue streams exist at this time. Future revenue would come from out-licensing, clinical, and commercial milestones as well as sales royalties for products developed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

DCx Biotherapeutics is a preclinical-stage biotechnology company developing multi-modal antibody drug conjugates (MM-ADCs) for genetically-defined cancers. Its core offering combines the proprietary MuSiC discovery platform (CRISPR, bioinformatics, and machine learning) with the CLARINET prodrug payload technology to engineer lesion-specific therapeutics that simultaneously target intracellular and cell-surface tumor proteins.

Product overview

DCx Biotherapeutics is a preclinical-stage discovery company developing Multi-Modal Antibody Drug Conjugates (MM-ADCs) for genetically-defined cancers. The company's core offering is built on the MuSic™ Platform, which integrates CRISPR-based functional screening with bioinformatics and machine learning to identify lesion-specific targets. The therapeutic approach combines functional antibodies with CLARINET™ payload technology (Cancer Lesion Adaptive Release via Intracellular Enzyme Trigger) to achieve synergistic targeting of both intracellular and cell-surface proteins. The company also licenses the SNIPRx® and STEP2 platforms from Repare Therapeutics for target discovery. The portfolio spans discovery platforms and payload technologies that work together to improve selectivity, potency, and tolerability over conventional ADCs.

Differentiator

Problem solved

Functional benefit

Brands

• MuSiC Platform: Integrated CRISPR, bioinformatics, and machine learning platform for identifying lesion-specific intracellular and cell-surface targets for synergistic therapeutic targeting.
• CLARINET Payload Technology

Products and services

• Multi-Modal Antibody Drug Conjugates (MM-ADCs) Next-generation precision drug conjugates that combine functional antibodies with biologically selective payloads to simultaneously target genetically-defined intracellular and cell-surface proteins, designed to improve efficacy, tolerability, and durability over conventional ADCs for genetically-defined cancer patients.
• MuSiC Platform Integrated discovery platform combining CRISPR-based high-throughput functional screening, bioinformatics, and machine learning to identify lesion-specific intracellular and cell-surface targets amenable to synergistic therapeutic intervention.
• CLARINET (Cancer Lesion Adaptive Release via Intracellular Enzyme Trigger) Prodrug payload technology that masks non-specific cytotoxics and selectively activates them via intracellular metabolic enzymes upregulated in lesion-specific tumors, providing a dual-logic gate that significantly expands the therapeutic window of ADCs.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• Repare Therapeutics Inc.coreTechnology or Integration · 1 May 2025DCx in-licensed Repare's discovery platforms including SNIPRx®, SNIPRx-surf, and STEP2 for discovering druggable intracellular and synergistic cell-surface targets. DCx also acquired undisclosed surfaceome targets, antibodies, and small molecule programs. Additionally, DCx retained approximately 20 scientific and support colleagues and acquired lease rights to laboratory facilities in Montreal.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Daiichi Sankyo: Japanese pharma major and ADC market leader (Enhertu, Datroway) with the largest ADC franchise globally. Comparable as the benchmark incumbent in the ADC space that DCx's MM-ADCs would need to differentiate against in genetically-defined cancer indications.
• AstraZeneca: Global pharma major and Daiichi Sankyo's ADC partner (Enhertu, Datroway) with the broadest oncology ADC pipeline. Comparable as a likely strategic partner or acquirer for DCx-style ADC platforms seeking to expand into novel lesion-specific indications.

Direct peers

• Mersana Therapeutics: Clinical-stage ADC developer using proprietary platforms (Dolasynthen, Immunosynthen) to create next-generation ADCs with improved tolerability and efficacy. Highly comparable to DCx's MM-ADC approach given shared focus on payload innovation and therapeutic-window expansion.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating ADCs (ISACs) that combine tumor-targeted antibodies with immune-activating payloads. Peer because of shared focus on multi-mechanism ADCs that go beyond conventional cytotoxic payloads.
• Zymeworks: Vancouver-based antibody therapeutics platform company developing multi-specific antibodies and ADCs. Direct peer because DCx's CEO Ali Tehrani and co-founders previously led ADC programs at Zymeworks that produced zanidatamab (Ziihera), and both companies pursue next-generation targeted oncology biologics using engineered antibodies.
• Repare Therapeutics: Clinical-stage precision oncology company whose synthetic-lethal and CRISPR-based discovery platforms (SNIPRx®, STEP2) were in-licensed by DCx in May 2025. Direct peer given overlapping synthetic-lethal target discovery technology and shared scientific staff, though Repare remains operationally independent.
• Pyxis Oncology: Clinical-stage ADC developer with multiple ADC programs in oncology, formed around antibody-drug conjugate technology. Comparable as a similarly-positioned (preclinical-to-clinical-stage) developer of next-generation ADCs against solid tumor targets.
• CytomX Therapeutics: Clinical-stage oncology company developing Probody®-masked ADCs and other conditionally-activated therapeutics. Direct peer because both companies pursue lesion/tumor-selective antibody activation strategies to improve therapeutic index — a concept analogous to DCx's CLARINET dual-logic gate.

Emerging players

• ProfoundBio: Emerging clinical-stage ADC developer with multiple programs in women's cancers and other solid tumors. Comparable to DCx as another next-generation ADC platform company built around proprietary antibody and linker-payload technologies targeting genetically-defined tumors.
• Tubulis: European preclinical/early-clinical ADC developer focused on novel payload-linker chemistries and stable conjugation technologies. Peer to DCx given parallel focus on engineering differentiated payload chemistry (analogous to CLARINET) to expand therapeutic index of ADCs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dcx-biotherapeutics-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DCx Biotherapeutics